A Phase 1 study to assess the safety, tolerability, and immunogenicity of VN-0200 after intramuscular injection in Japanese healthy adults and elderly subjects
Completed
- Conditions
- Prevention of respiratory syncytial virus
- Registration Number
- jRCT2031210069
- Lead Sponsor
- DAIICHI SANKYO Co.,Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
- Japanese healthy subjects.
- Age >=20 and <=50 years upon providing informed consent at step1 or Age >=65 and <=80 years upon providing informed consent at step2.
- Body mass index (BMI) >=18.0 and <30.0 kg/m2 at screening.
Exclusion Criteria
- Subjects with a history of anaphylaxis or severe allergies due to food, medicine, insect bites, cosmetics, or vaccination
- Having alcohol or drug dependence etc.
Study & Design
- Study Type
- Interventional
- Study Design
- parallel assignment
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method